A Phase I Study of the Fully Human, Fragment Crystallizable-engineered, Anti-CD-33 Monoclonal Antibody BI 836858 in Patients with Previously-treated Acute Myeloid Leukemia

Overview

Journal Haematologica

Specialty Hematology

Date 2021 Dec 2

PMID 34854276

Citations 6

Authors

Sumithira Vasu

Jessica K Altman

Geoffrey L Uy

Martin S Tallman

Ivana Gojo

Gerard Lozanski

Ute Burkard

Annika Osswald

Pamela James

Bjorn Ruter

William Blum

Affiliations

Soon will be listed here.

Citing Articles

Preclinical Characterization of the Anti-Leukemia Activity of the CD33/CD16a/NKG2D Immune-Modulating TriNKET CC-96191.

Lunn-Halbert M, Laszlo G, Erraiss S, Orr M, Jessup H, Thomas H Cancers (Basel). 2024; 16(5).

PMID: 38473239 PMC: 10931532. DOI: 10.3390/cancers16050877.

Immunotherapy in hematologic malignancies: achievements, challenges and future prospects.

Tang L, Huang Z, Mei H, Hu Y Signal Transduct Target Ther. 2023; 8(1):306.

PMID: 37591844 PMC: 10435569. DOI: 10.1038/s41392-023-01521-5.

Antibody therapies for the treatment of acute myeloid leukemia: exploring current and emerging therapeutic targets.

Morse J, Rios M, Ye J, Rios A, Zhang C, Daver N Expert Opin Investig Drugs. 2023; 32(2):107-125.

PMID: 36762937 PMC: 10031751. DOI: 10.1080/13543784.2023.2179482.

An open-label, phase I/II trial to determine the maximum tolerated dose and investigate safety, pharmacokinetics and efficacy of BI 836858, an unconjugated anti-CD33 monoclonal antibody, in combination with decitabine in patients with acute myeloid....

Fiedler W, Montesinos P, Schliemann C, Middeke J, Vasu S, Scholz C Haematologica. 2022; 107(12):2977-2982.

PMID: 36005556 PMC: 9713566. DOI: 10.3324/haematol.2022.281128.

A phase I/II multicenter, open-label, dose escalation and randomized trial of BI 836858 in patients with low- or intermediate-1-risk myelodysplastic syndrome.

Komrokji R, Carraway H, Germing U, Wermke M, Zeidan A, Fu E Haematologica. 2022; 107(11):2742-2747.

PMID: 35734924 PMC: 9614517. DOI: 10.3324/haematol.2021.280500.

References

Sutherland M, Yu C, Lewis T, Miyamoto J, Morris-Tilden C, Jonas M . Anti-leukemic activity of lintuzumab (SGN-33) in preclinical models of acute myeloid leukemia. MAbs. 2010; 1(5):481-90. PMC: 2759498. DOI: 10.4161/mabs.1.5.9288. View

Sekeres M, Lancet J, Wood B, Grove L, Sandalic L, Sievers E . Randomized phase IIb study of low-dose cytarabine and lintuzumab versus low-dose cytarabine and placebo in older adults with untreated acute myeloid leukemia. Haematologica. 2012; 98(1):119-28. PMC: 3533673. DOI: 10.3324/haematol.2012.066613. View

Stringaris K, Sekine T, Khoder A, Alsuliman A, Razzaghi B, Sargeant R . Leukemia-induced phenotypic and functional defects in natural killer cells predict failure to achieve remission in acute myeloid leukemia. Haematologica. 2014; 99(5):836-47. PMC: 4008119. DOI: 10.3324/haematol.2013.087536. View

Eddy J, Krukowski K, Janusek L, Mathews H . Glucocorticoids regulate natural killer cell function epigenetically. Cell Immunol. 2014; 290(1):120-30. PMC: 4128186. DOI: 10.1016/j.cellimm.2014.05.013. View

Feldman E, Kalaycio M, Weiner G, Frankel S, SCHULMAN P, Schwartzberg L . Treatment of relapsed or refractory acute myeloid leukemia with humanized anti-CD33 monoclonal antibody HuM195. Leukemia. 2003; 17(2):314-8. DOI: 10.1038/sj.leu.2402803. View

Borthakur G, Rosenblum M, Talpaz M, Daver N, Ravandi F, Faderl S . Phase 1 study of an anti-CD33 immunotoxin, humanized monoclonal antibody M195 conjugated to recombinant gelonin (HUM-195/rGEL), in patients with advanced myeloid malignancies. Haematologica. 2012; 98(2):217-21. PMC: 3561428. DOI: 10.3324/haematol.2012.071092. View

Castaigne S, Pautas C, Terre C, Raffoux E, Bordessoule D, Bastie J . Effect of gemtuzumab ozogamicin on survival of adult patients with de-novo acute myeloid leukaemia (ALFA-0701): a randomised, open-label, phase 3 study. Lancet. 2012; 379(9825):1508-16. DOI: 10.1016/S0140-6736(12)60485-1. View

Raza A, Jurcic J, Roboz G, Maris M, Stephenson J, Wood B . Complete remissions observed in acute myeloid leukemia following prolonged exposure to lintuzumab: a phase 1 trial. Leuk Lymphoma. 2009; 50(8):1336-44. DOI: 10.1080/10428190903050013. View

Walter R . Investigational CD33-targeted therapeutics for acute myeloid leukemia. Expert Opin Investig Drugs. 2018; 27(4):339-348. DOI: 10.1080/13543784.2018.1452911. View

10.

Williams B, Law A, Hunyadkurti J, Desilets S, Leyton J, Keating A . Antibody Therapies for Acute Myeloid Leukemia: Unconjugated, Toxin-Conjugated, Radio-Conjugated and Multivalent Formats. J Clin Med. 2019; 8(8). PMC: 6723634. DOI: 10.3390/jcm8081261. View

11.

Feldman E, Brandwein J, Stone R, Kalaycio M, Moore J, OConnor J . Phase III randomized multicenter study of a humanized anti-CD33 monoclonal antibody, lintuzumab, in combination with chemotherapy, versus chemotherapy alone in patients with refractory or first-relapsed acute myeloid leukemia. J Clin Oncol. 2005; 23(18):4110-6. DOI: 10.1200/JCO.2005.09.133. View

12.

Vasu S, He S, Cheney C, Gopalakrishnan B, Mani R, Lozanski G . Decitabine enhances anti-CD33 monoclonal antibody BI 836858-mediated natural killer ADCC against AML blasts. Blood. 2016; 127(23):2879-89. PMC: 4900955. DOI: 10.1182/blood-2015-11-680546. View

13.

Hills R, Castaigne S, Appelbaum F, Delaunay J, Petersdorf S, Othus M . Addition of gemtuzumab ozogamicin to induction chemotherapy in adult patients with acute myeloid leukaemia: a meta-analysis of individual patient data from randomised controlled trials. Lancet Oncol. 2014; 15(9):986-96. PMC: 4137593. DOI: 10.1016/S1470-2045(14)70281-5. View

14.

Romain G, Senyukov V, Rey-Villamizar N, Merouane A, Kelton W, Liadi I . Antibody Fc engineering improves frequency and promotes kinetic boosting of serial killing mediated by NK cells. Blood. 2014; 124(22):3241-9. PMC: 4239333. DOI: 10.1182/blood-2014-04-569061. View

15.

Kumai T, Oikawa K, Aoki N, Kimura S, Harabuchi Y, Kobayashi H . Assessment of the change in cetuximab-induced antibody-dependent cellular cytotoxicity activity of natural killer cells by steroid. Head Neck. 2014; 38(3):410-6. DOI: 10.1002/hed.23906. View